MedPath

FDA Approves Krystal Biotech's Vyjuvek, a Topical Gene Therapy for Dystrophic Epidermolysis Bullosa

  • The FDA has approved Vyjuvek, Krystal Biotech's topical gene therapy, marking the first treatment of its kind for dystrophic epidermolysis bullosa.
  • Vyjuvek is approved for patients aged six months and older with either recessive or dominant forms of dystrophic epidermolysis bullosa.
  • Clinical trials showed Vyjuvek completely healed wounds in approximately 65% of patients, compared to 21.6% in the placebo group.
  • Krystal Biotech anticipates Vyjuvek will be available in the U.S. in Q3 2023, with plans to provide access to all U.S. patients.
The U.S. Food and Drug Administration (FDA) has approved Krystal Biotech Inc's Vyjuvek, a first-of-its-kind topical gene therapy for patients with dystrophic epidermolysis bullosa (DEB). This rare and severe genetic skin disorder, often presenting at birth, leads to open wounds, increasing the risk of skin infections, vision loss, scarring, and potentially fatal skin cancer. The approval marks a significant advancement for a condition where most affected individuals rarely survive beyond 30 years of age.
Vyjuvek is indicated for patients aged six months and older, suffering from either recessive or dominant forms of DEB. The therapy's approval is based on data from an early-to-mid-stage study and a pivotal late-stage trial involving 31 patients.

Clinical Trial Results

The late-stage study demonstrated that Vyjuvek led to complete wound healing in approximately 65% of participants, significantly higher than the 21.6% observed in the placebo group. These results underscore the potential of Vyjuvek to address the unmet medical needs of DEB patients.

Commercialization and Availability

Krystal Biotech anticipates that Vyjuvek will be available in the United States in the third quarter of 2023. CEO Krish Krishnan stated, "We have been preparing for a commercial launch for the last 18 months if not longer. Our intent is to provide access to all the patients if possible in the United States."

Disease Burden and Patient Population

Dystrophic epidermolysis bullosa affects an estimated 9,000 to 10,000 people globally, with approximately 3,000 patients residing in the United States, according to Krystal Biotech. The company has not yet disclosed the pricing for Vyjuvek.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Ryoncil, First Mesenchymal Stromal Cell Therapy for Pediatric Steroid-Refractory Acute Graft-versus-Host Disease

The FDA has approved Ryoncil (remestemcel-L-rknd) as the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients.

Neurocrine Biosciences' Crinecerfont Receives FDA Approval for Congenital Adrenal Hyperplasia

The FDA has approved Crinecerfont, developed by Neurocrine Biosciences, as the first drug in decades for congenital adrenal hyperplasia (CAH).

FDA Approves Checkpoint Therapeutics' Unloxcyt (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma

The FDA has granted approval to Checkpoint Therapeutics' Unloxcyt (cosibelimab-ipdl) for the treatment of advanced cutaneous squamous cell carcinoma (cSCC).

uniQure Receives FDA Nod for Accelerated Approval Pathway for Huntington's Disease Gene Therapy

uniQure secured FDA agreement to pursue accelerated approval for its Huntington's disease gene therapy, potentially expediting treatment availability.

FDA Approves PTC Therapeutics' Kebilidi, First Gene Therapy for AADC Deficiency

The FDA has granted accelerated approval to PTC Therapeutics' Kebilidi (eladocagene exuparvovec-tneq) for treating AADC deficiency in patients aged 18 months and older.

Biofrontera's Ameluz Demonstrates High Efficacy in Phase III sBCC Trial

Biofrontera's Ameluz-PDT therapy met the primary endpoint, showing 65.5% success in complete clearance of superficial basal cell carcinoma (sBCC) lesions, compared to 4.8% with placebo.

Biofrontera's Ameluz Demonstrates Success in Phase III sBCC Trial, Stock Surges

Biofrontera's Ameluz-PDT therapy met the primary endpoint in a Phase III trial for superficial basal cell carcinoma (sBCC), showing significant clinical and histological clearance.

Ultragenyx's Setrusumab Receives FDA Breakthrough Therapy Designation for Osteogenesis Imperfecta

Ultragenyx's setrusumab (UX143) has been granted Breakthrough Therapy Designation by the FDA to reduce fracture risk in osteogenesis imperfecta (OI) patients.

FDA Approves CRISPR-Based Gene Therapy Casgevy for Transfusion-Dependent Beta Thalassemia

The FDA has approved Casgevy, a CRISPR-based gene therapy, for treating transfusion-dependent beta thalassemia, marking the second major U.S. approval for CRISPR technology.

FDA Approves First Gene Therapy, Vijuvek, for Rare Skin Disease Epidermolysis Bullosa

The FDA has approved Vijuvek, a topical gene therapy developed by Krystal Biotech, as the first treatment of its kind for epidermolysis bullosa (EB).

Reference News

[1]
UPDATE 1-U.S. FDA approves Krystal Biotech's skin disorder gene therapy
finance.yahoo.com · May 19, 2023

The FDA approved Krystal Biotech's Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa, a sever...

[2]
U.S. FDA approves Krystal Biotech's skin disorder gene therapy
news.yahoo.com · May 19, 2023

The FDA approved Krystal Biotech's Vyjuvek, a first-of-its-kind topical gene therapy for dystrophic epidermolysis bullos...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy